Bayer AG (BAYRY) reports modest sales growth and debt reduction amid financial headwinds and strategic challenges.

Bayer's CEO, Bill Anderson, faces escalating investor scrutiny to reverse the company's forecasted earnings decline. Tasked ...

The company expects improved performance from 2026 onwards. Alongside its four existing strategic priorities, the company is adding ...

Bayer guides for lower earnings this year but an improved performance starting in 2026, after swinging to a Q4 net loss of ...

Expects EBITDA before special items and core EPS to decline. CEO Bill Anderson said, “We all look forward to being able to pay out a larger ...

As health lawsuits cut into corporate profits, pesticide giant pushes Cancer Gag Act legislation to cover their losses ...

Facing thousands of lawsuits and seeking protection from lawmakers, Bayer is using ads, lobbying and third-party mouthpieces ...

The nine Republican members of the Missouri Senate carry enough firepower to stage a prolonged legislative filibuster to stop ...

Sales declined 0.9% organically, with volumes down 4% while prices rose 3.1%. For 2025, Bayer projects sales growth of 2% to ...

Global Herbicide Market Poised for Strong Growth, Fueled by Demand for Efficient Agricultural Solutions and Non-Crop ...

Winning passage of the legislation in Missouri is especially important because most state-level cases are filed here because it is the national home of Bayer. When a Missouri-based corporation is ...